The concentration of Health research and innovation across EU regions

di Claudio Cozza* e Monica Plechero°

Abstract

Health research and innovation (R&I) is attracting the attention of EU, national and regional policymakers. As Health policies are becoming a public policy priority – targeting not only social needs but also the overall economic development of EU countries – Health R&I have been identified as key areas of investment. However, despite the attempts to reduce inequalities also in this field, a strong concentration of Health R&I across EU regions still exists. The paper provides recent and novel empirical evidence on the topic, describing the concentration of Health patents, publications and EU project participation in top EU regions. Regional data help in assessing that, also in the Health sector, concentration is not only a cross-country but also a within-country issue.

Keywords: EU regions, Research, Health.
JEL classification: O33, R12.

La concentrazione delle attività di innovazione e ricerca sanitaria nelle regioni UE

Sommario

La ricerca e innovazione (R&I) nel settore della salute sta attrattendo sempre più l’attenzione dei policymakers nazionali, regionali ed europei, divenendo un’area strategica di investimento. Le politiche sulla salute sono infatti una priorità pubblica che ha come target non solo i bisogni sociali ma anche lo sviluppo economico nei paesi UE. Sebbene ci siano vari tentativi di ridurre le disuguaglianze all’interno della comunità europea, in questo settore esiste ancora una forte concentrazione in alcune aree rispetto ad altre. L’articolo fornisce nuove e recenti evidenze empiriche sull’argomento mostrando come la diversa distribuzione di attività brevettuali, pubblicazioni e partecipazione a progetti di ricerca non è solo divergente fra paesi ma anche fra regioni appartenenti ai singoli paesi UE.

Parole chiave: regioni UE, Ricerca, Salute.
Classificazione JEL: O33, R12.

* This work was supported by European Commission [Grant Agreement No 643574] under the European Union Horizon 2020.
* Istituto Ricerche, AREA Science Park, Trieste (IT), claudio.cozza@areasciencepark.it.
° DISEI, Università degli Studi di Firenze, Firenze (IT), monica.plechero@unifi.it.
Introduction

Over the last years, European policymakers – both at the national and at the sub-national level – have widened their perspective regarding Health. From the generic attention to EU citizens’ healthcare, the focus has shifted towards a more complex framework where Health is an increasingly crucial social need. Already in 2007 with the white paper “Together for Health” (EC, 2007), the European Commission has identified the most crucial challenges regarding Health in its area: the increase in chronic diseases, the growing technological costs to face Health challenges and especially an ageing population. The consideration of those issues has then been included in the wider Europe 2020 Strategy (EC, 2013a), where two additional policy points have been highlighted:

- Despite a generic increase in health conditions across EU countries, also an increase in inequality can be detected: «poorer and disadvantaged people die younger and suffer more often from disability and disease».
- As a consequence, the concept of “investing in Health” has to be further developed.

Indeed, such a shift in the analytical viewpoint, where Health policies should represent even more than in the past, a pivotal asset for the growth and cohesion of world society, can be found in other policy documents. As stated by the OECD (2014, p.9), «European countries have achieved significant gains in population health, but there remain large inequalities in health status both across and within countries». The efforts made by EU governments are reflected in several recent indicators: Health represents the second most important budget line in EU countries; overall the 73% of Health expenditures is funded by the public sector; and one employee out of 10 works in this sector. Therefore, especially in a EU society where life expectancy constantly grows, investing in Health has to be considered a compulsory task for achieving economic prosperity and social cohesion.

Following this logic, Health is no more intended as a simple value in itself and it is becoming a public policy priority in the EU. For this reason, it is more and more important to focus on the economic aspects of Health. Investing in the efficiency of Health system and especially on prevention will bring also increases in work productivity and will reduce social inequalities. This is especially true when looking at poorer areas and performing an economic analysis at the sub-national level (Purohit, 2016). Furthermore, local public policies are to provide adequate Health services (Williams,
which imply investments in Health Research and Innovation (R&I). Such goals are strictly related to the capability of R&I actors to make substantial advancements in the field (Intereconomics Forum, 2015). Not by chance, Health (together with Demographic change and Well-being) is one of the societal challenges of the EU Horizon 2020 research programme. Health goals are, therefore, intrinsically contained in the EU R&I strategy.

Given the cumulative nature of R&I assets, however, EU countries and especially EU regions are expected to perform very differently. Even more than in general terms, the convergence of EU countries and regions in R&I has to be achieved with strong policy tools (Goecke & Hüther, 2016). Not by chance, then, the EU Horizon 2020 Programme addresses the inequalities in the field of Health R&I, in order to find the right policy measures to reduce the gap among EU countries and regions. Such a gap might be particularly significant in the Health R&I domain, thus implying a minor capacity of some national and/or regional Health systems to respond adequately to societal contextual needs. Following the approach mentioned above, less R&I in Health systems might lead to the worsening of the work and social conditions of some EU areas.

The key role of Health is also confirmed by the fact that it is one of the most recurrent priorities for EU regions’ smart specialization strategies (S3, see Sörvik & Kleibrink, 2015). Indeed regions in almost all EU countries claim Health as their S3 priority. However, different regions might refer to specific – and very different – sub-areas of Health, targeting it from very different perspectives. That is, for instance, referring to Health when dealing with the Pharmaceuticals, Biotech or Medical technology sectors, eventually key in their territory; or simply when dealing with their ageing population; or maybe meaning the introduction in their systems of healthcare innovations, such as e-Health.

To tackle such a challenging perspective, a deeper knowledge about the availability and quality of Health indicators across is needed. While the World Health Organisation (WHO) European regional office has developed an extensive exercise for developing adequate healthcare indicators (WHO, 2012), measures of Health R&I in Europe are very scarce. We claim that such limited evidence is in contradiction with the idea of smarter investments in Health and might eventually bring to incorrect policy decisions in EU countries and regions. In particular, a poor knowledge about Health R&I performances and the use of inadequate indicators in Europe might
hide the real inequalities in the sector, thus extending instead of reducing the gap between top and least performing countries.

This paper aims at better understanding Health R&I inequalities, including their technological and economic dimensions, in Europe. It is structured as follows: in section 2 we report the main data limitations and the methodological problems in mapping Health R&I in the EU; in section 3, using novel data, we provide an overview of the current situation in EU Health R&I, showing the concentration and polarisation across countries and regions; in section 4 we provide some conclusions and policy remarks.

1. The (limited) mapping of Health R&I in the EU

The difficulty in measuring Health R&I is intrinsically related to its definition. Considering the most relevant measure – that is Health R&D – a warning comes from an OECD report related to R&D in Health (OECD, 2001). It is there stated that «in the widest sense we are interested in all R&D which is relevant to human health. Here there are no generally accepted international definitions or guidelines on coverage. There are few (if any) areas of investigations which can “logically” be excluded from possible relevance to health – perhaps cosmology». To overcome such a problem, the WHO in 2013 organised an “Informal workshop on monitoring financial flows in support of health research & development”. This workshop has reinforced, in particular, the idea of overcoming the limitations of data availability for Health R&D. Following the WHO workshop, the newly-born Global Observatory for Health R&D by OECD and WHO has already started to work on better indicators for measuring Health R&D1. First results of the Observatory have led to estimations of Health R&D and clinical trials provided for all world countries in a recent Lancet

1 The idea behind this Global Observatory is to monitor and analyze relevant information on Health R&D, building on national and regional observatories (or equivalent functions) and existing global data collection mechanisms with a view to contributing to the identification of gaps and opportunities for health R&D.
publication (Røttingen et al., 2013). Such estimations confirm the high degree of concentration in the EU. As shown in figure 1, the highest shares of expenditure in Health R&D on GDP are detected for most technologically advanced EU countries, including Sweden, Denmark, UK and central EU countries such as Germany, Netherlands and Belgium. With the notable exception of Slovenia and partially Hungary, the least performing countries belong to Eastern Europe. However, according to the Observatory itself, a lot of work still remains to be done in order to provide stakeholders with the best information to monitor and assess Health R&I in all countries and regions.

*Fig. 1 – Health R&D (as a percentage of GDP) in EU countries*

Source: Own elaboration on Røttingen et al. (2013). Year: 2010 or latest available year.

For mapping Health R&I, there are also other methodological problems. On the one side, this is related to the complexity and specificity of the sector: Health includes manufacturing (e.g. the pharmaceuticals) and services (e.g. the hospitals) activities; it includes very strong investment both by the public and by the private bodies; it relies on strong propriety protection for some technological aspects, while it implies the full accessibility of knowledge for others; it affects both the macro level (the society as a whole) and the micro level (companies, professionals, individual citizens). On the other side, then, there is a more practical problem related to the institutional level at which the policies decisions are taken: while Health policies often involve decisions at the NUTS2 regional level (e.g. using EU
Structural Funds, see EC, 2015), many indicators which should sustain the decision processes only exist at the country level.

In fact, the joint analysis of R&I figures at the NUTS2 regional and sectorial (Health) level is not straightforward. Usually the deepening of one dimension (i.e. the regional one) excludes that of the other one (the sectorial). Indeed the most important publication on the innovativeness of EU regions (that is the Regional Innovation Scoreboard) does not fully cover any specific sector. Regional/sectorial analyses are usually included in case studies or in reports covering one country only or other limited breakdowns (EC, 2013b). Providing adequate map of Health R&I in all NUTS2 regions has been therefore one of the main point of a Horizon 2020 project, aimed at filling in the informative gap in terms of Health at the regional level, in the EU².

2. An overview of the concentration and disparities of Health R&I in Europe

The mapping of Health R&I has been undertaken selecting the most common indicators in the economics of innovation (Smith, 2005): scientific publications and patent applications. Although it is arguable that both indicators concern more research than innovation, also in the Health sector, it is clear that they catch two different aspects of the R&I process. It is in fact expected that publications reflect more the public sector involvement, while patents are closer to the private engagement in R&I (Callon, 1994). Although this distinction has not to be intended as normative, regional data on Health patents and publications give a confirmation of it. In table 1 we show the correlation coefficients between regional Health outcomes (pa-

² The project “European regions network for Health Research & Innovation”, funded by the Horizon 2020, having as main goal to propose new initiatives and concrete approaches to EU, national and regional decision-makers in Health to: i) reduce the gaps in Health R&I across the EU regions, ii) to increase the participation in Horizon 2020, and iii) to facilitate synergies between Horizon 2020 (H2020) and European Structural & Investment Funds (ESIFs).
tents and publications) and the breakdown of the main innovation input variable, that is R&D expenditure. The breakdown allows to identify the share of R&D performed in each region by the three main sectors: business, government and higher education (BERD, GOVERD and HERD respectively). In table 1 it is clearly shown as the business sector has a higher correlation coefficient with patents, while the government sector with publications. Intermediate values come out for the higher education sector, and this reflects the specificity of universities for which both outcomes are relevant.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BERD R&amp;D</td>
<td>0.7906*</td>
<td>0.6039*</td>
</tr>
<tr>
<td>GOVERD R&amp;D</td>
<td>0.6829*</td>
<td>0.7089*</td>
</tr>
<tr>
<td>HERD</td>
<td>0.7488*</td>
<td>0.9074*</td>
</tr>
</tbody>
</table>

BERD (business expenditure in R&D), GOVERD (government expenditure in R&D) and HERD (higher educational R&D expenditure) refers to year 2011 because of better data quality with respect to previous years. Correlations are significant at 1% level.

In figures 2 and 3 we show the results of the mapping. The maps show a clear concentration of Health R&I in a limited number of countries and regions. Northern EU countries always show the highest performances, although the two maps do not perfectly coincide. Only four countries (Denmark, Ireland, the Netherlands and Sweden) rank at the top in both indicators, suggesting that specialisation in the sector might be more relevant than the size of the national economies. In fact, several large EU countries only rank in the second quartile, in either one indicator or both. As expected, the almost totality of least performing countries are Eastern EU ones, confirming their urgent need to fill in the gap with the rest of Europe. Not by chance, policy instruments\(^3\) at the EU level have

\(^3\) The definition of Widening countries, which are currently devoted special attention and resources (e.g. a dedicated budget of the Horizon 2020 programme), can be found in EC, 2015, or at: https://ec.europa.eu/programmes/horizon2020/en/h2020-section/spreading-excellence-and-widening-participation)
been recently adopted to tackle the issue and try to help catching-up countries in R&I.

Fig. 2 – Health publications and patents in EU-28 countries, by population

Scientific publications  EPO patent applications

Source: Own elaboration on European Commission – DG Research data. Patents and publications have been classified by FP7 Health thematic priority. Year: average 2008-2012 for publication, average 2008-2010 for patents. Colours reflect the quartiles.

Fig. 3 – Health publications and patents in EU-28 regions, by population

Scientific publications  EPO patent applications

Source: Own elaboration on European Commission – DG Research data. Patents and publications have been classified by FP7 Health thematic priority. Year: average 2008-2012 for publication, average 2008-2010 for patents. Colours reflect the quartiles. Grey colour refers to missing data.
However, what emerges by looking at regional maps is that concentration is not only a cross-countries matter. Indeed, in almost all countries there is a high polarisation of regions in terms of Health R&I outcomes. If we look at regional publications, we can observe that almost all countries have at least one top region, either belonging to the first quartile (mostly in the case of Western EU countries) or to the second one (especially for Eastern EU ones). It is instead in the case of patent applications that the cross-country and within-country polarisations tend to coincide: top regions are almost all located in Central Europe (including Germany, BENELUX but also parts of France and Northern Italy) and in Northern countries (Ireland, UK and Scandinavian ones). In other words, the regional patent map strongly reflects the industrialisation of EU countries and its already known concentration. While, concerning scientific publications, a more “democratic” spread of the indicator might suggest a positive role of public and higher education sectors engagement in Health R&I.

The cross- and within-countries polarisation is then appearing also in the main indicators of the funding of Health R&I. Figure 4 shows the distribution of FP7 Health project participants (in the whole 2007-2013 period). Again, Western EU countries show both the highest average values but also a great disparity between their top and least performing regions. In the group of Widening countries mentioned above, only Slovenia and Czech Republic show performances in line with some of the non-Widening ones.

*Fig. 4 – Regional dispersion of FP7 Health projects participation, per million population: average, minimum and maximum values.*

Source: EC, CORDA.
Such a figure helps in better understanding the real extent of concentration in European Health R&I. In fact, couples of countries with a very similar average can have a completely different situation behind. We make some examples. A good performing country as the Netherlands has a higher average than Denmark; however, the top Danish region achieves a maximum score of more than 140 projects per million population, while the top Dutch one does not go beyond 120. Even more, the top region in Europe (London) belongs to a country (UK) whose average is not particularly high. Then, a low performing country in terms of average, that is the Czech Republic, shows a top region that is in line with countries with higher averages (e.g. Slovenia and Ireland) and even above large countries (e.g. Italy).

Of course, having a low average might signal the strong unbalances that exist in some EU countries. Indeed, many countries have just one or two spots of better performance, as compared to a very poor environment in the rest of their territories. The joint analysis of the national and the NUTS2 regional level, then, is even more needed to depict the concentration and unbalances of Health R&I, in both top and least performing countries.

The figures shown confirm the idea that less performing regions and countries might need to catch-up and reinforce their R&I performance. As already mentioned, in the Horizon 2020 there is a small share of the overall budget dedicated to Widening countries, including all Eastern countries plus Luxembourg and Portugal. The definition of Widening country follows the EC approach of measuring in a synthetic way the outcomes of the R&I process, as well as its excellence. Indeed the definition derives from the composite indicator of Research Excellence, put forward in a EC-JRC report (2013) which aims at measuring research excellence in Europe, at country level, from a multiple point of view. The (top) quality of scientific and technological outputs concerns four different typologies of research activities: highly-cited publications; high-quality patent applications; quality of universities and research institutes; and capacity to receive prestigious grants such as the ERC ones.

This indicator has not only an intrinsic motivation that is to quantify altogether the different dimensions of research excellence. From a policy perspective, the indicator provides a synthetic overview of R&I to better understand which European countries are less performing and therefore in need of specific policy support. Not by chance, Widening countries are those below the 70% of the EU average.
In the framework of the RegHealth-RI project, an attempt has been made to replicate the EC-JRC indicator for the Health sector, with minor adaptations. Unfortunately, the regionalisation of this indicator – that we consider very important for policy support reasons – is not measurable for strong lack of data⁴. At the national level, the Health Research Excellence indicator has been calculated as shown in figure 5, where it is also compared to the original EC-JRC one.

![Fig. 5 – Comparison of variables included in the composite indicators](image)

<table>
<thead>
<tr>
<th>Composite indicator research excellence (EC-JRC, 2013)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Top 10% most cited publications (2000-2007)</td>
</tr>
<tr>
<td>(3) PCT Patents per population (2000-2008)</td>
</tr>
<tr>
<td>(4) ERC Grants per public R&amp;D (2007-2011)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RegHealth-RI composite indicator research excellence</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Health Top 10% most cited publications (2008-2009)</td>
</tr>
<tr>
<td>(2) Health TOP universities and PROs (2007-2012)</td>
</tr>
<tr>
<td>(3) Health PCT patents per population (2008-2010)</td>
</tr>
<tr>
<td>(4) Health ERC Grants per public R&amp;D (GERD+HERD) (updated years)</td>
</tr>
</tbody>
</table>

The intensity of the Health Research Excellence indicator is displayed, for all EU countries, in figure 6, where again the four colours represent the quartiles of the distribution.

Although the composite indicator of Health research excellence at country level appears similar to the EC-JRC one, important differences emerge. For some top performing countries, the Health indicator inverts the overall ranking: Italy goes up from the second to the first quartile, while for Sweden the opposite happens. Overall, the predominance of Nordic and Central-Western EU countries is confirmed. The last quartile includes only Eastern European countries.

⁴ To make an example, the lack of information of most cited publications in Health available for all regions. Moreover, given the problematic issues identified also at the national level for some variables, the risk of calculating a regional indicator was to increase even more its unreliability.
All in all, we can observe that such a picture almost overlaps with those of figure 2. This is not surprising, as it merges similar information that we have presented there and similar to those in figure 4. In other words, we believe that such a composite indicator might hide two levels of differences:

- The specific performance of single countries in one indicator (e.g. publications or patents or EU project participation);
- The within-countries regional polarisation, as we have shown in figures 3 and 4.

In practical terms, it is suggested that for those widening regions with low levels of scientific outcomes (health publications) public policies should be aimed at developing local competences. A direct objective might be that of increasing the share of highly educated workers on total population. Vice versa, those widening regions with good scientific performance but that show low performances in terms of health patents, it is suggested to introduce more policies aimed at the networking with partners from advanced regions with stronger innovation capabilities, possibly via public-private partnerships.

Therefore, from a policy perspective we suggest that a deeper and detailed analyses of R&I variables can be more useful than a synthetic picture of the overall phenomenon. Detailed analyses can better inform national and regional policymakers about their specific (e.g. regional & sectorial) strengths and weaknesses, to adopt the most suitable policies. One of the aims of the Horizon 2020 project from which this paper originated was to provide a sectoral and regional breakdown of health R&I variables. The
first descriptive outcomes have been presented in this paper. At the moment, data do not allow further analyses, as most of variables are still available at the regional or at the sectoral level alternatively. To proceed with detailed analyses suggested here, it is recommended that additional evidence, especially on the input side of health R&I, is gathered. The preliminary outcomes of this paper suggest that this analytical direction can be fruitful, as it allows to better target innovation policies. Not only distinguishing between top and least performing regions, but also differentiating different types of regions within these two categories.

Conclusions

In this paper, we have shown the degree of concentration of Health R&I in EU countries and regions. Being R&I more and more key in shaping EU Health policies, shifting from the pure measure of healthcare to a wider concept of “investing in Health”, we believe this mapping is of great value. This is particularly relevant for less performing countries (so called Widening) that have and deserve dedicated funding and resources. In fact, their R&I performances are still very far from that of most advanced EU countries.

However, we also suggest that such a Widening definition based on composite indicators (EC-JRC, 2013) might be misleading and a wider analytical approach should be followed. Being Health, on the one side, and R&I, on the other side, increasingly key issues for EU policy.

In addition, given the growing relevance of policies at the regional level, also in the framework of Smart Specialisation Strategies, there is the need of improving measures of regional & sectorial Health R&I. In fact, these sub-national measures might catch specific Health activities and subsectors which singularly or jointly may contribute to the development of some regions, better than standard classifications (e.g. NACE codes). Regional data remain also crucial to identify whether the polarisation of R&I outcomes happens even within countries, also the most developed ones.

References

OECD (2001). Measuring Expenditure on Health-related R&D.

120